Unit­ed Ther­a­peu­tics pays $800M-plus to grab Are­na’s PhI­II PAH drug

7 years ago
Pharma

Ab­b­Vie en­lists pro­tein degra­da­tion ex­perts at Mis­sion for a new bet on Alzheimer's, Parkin­son's

7 years ago
Pharma

Part­nered with No­var­tis, tiny Ca­dent jumps out of stealth with $40M round for its CNS pipeline

7 years ago
Financing
Startups

What's com­ing? Paz­dur, Marks and Wood­cock dis­cuss FDA changes

7 years ago
Pharma

Can a Nek­tar ri­val make it on Nas­daq with a $100M IPO? Syn­thorx is giv­ing it a shot

7 years ago
Financing

Pfiz­er los­es key Lyri­ca patent bat­tle in the UK; Kleo Phar­ma clos­es $21M Se­ries B round

7 years ago
News Briefing

FDA press­es its cam­paign against rogue re­gen­er­a­tive med play­ers, cites Stem­Genex for il­le­gal sales

7 years ago
Pharma
Cell/Gene Tx

Elud­ed by clear suc­cess in esophageal car­ci­no­ma, Mer­ck touts sub­group OS win for Keytru­da

7 years ago
R&D

Deer­field bankrolls an $80M re­search cen­ter at Dana-Far­ber de­vot­ed to pro­tein degra­da­tion

7 years ago
Discovery

Can a 're­dis­cov­ered' drug from In­dia make it big in US im­munol­o­gy space? Dan Brad­bury and his team at Equi­l­li­um want ...

7 years ago
Financing

Cel­gene dou­bles down on Drag­on­fly­'s nat­ur­al killer tech, ex­pand­ing in­to sol­id tu­mors with an in­jec­tion of ...

7 years ago
Pharma

Did No­var­tis get $150M worth of pos­i­tive PhII car­dio da­ta from Akcea?

7 years ago
R&D

South Ko­re­an reg­u­la­tor sus­pends Sam­sung Bi­o­Log­ic­s' stock, cit­ing ac­count­ing vi­o­la­tions

7 years ago
R&D
Pharma

In­tro­duc­ing SVB Leerink: SVB bags Leerink Part­ners for $280M as a ma­jor play­er spreads its wings dur­ing a life ...

7 years ago
Deals

Roche wins speedy FDA re­view for Tecen­triq; South Ko­re­an au­thor­i­ties to look in­to Sam­sung Bi­o­Log­ics ac­count­ing ...

7 years ago
News Briefing

CStone braves the HKEX with late-stage plans brew­ing for new­ly beefed up I/O pipeline

7 years ago
Financing
China

New can­cer tar­get? GSK high­lights on­col­o­gy am­bi­tions with its move in­to the clin­ic with RIP1 drug for pan­cre­at­ic ...

7 years ago
R&D

As­traZeneca makes $1B-plus in cash-and-stock deal grant­i­ng So­bi US rights to RSV drug Synagis

7 years ago
R&D

Kymera rais­es $65M from glob­al syn­di­cate as it aims for the clin­ic with pro­tein degra­da­tion tech

7 years ago
Financing

As Roivant’s uni­corn val­u­a­tion swells to $7B, Ra­maswamy scoops up $200M to back a new burst of star­tups

7 years ago
Financing

On the heels of an Eli Lil­ly deal, NextCure’s hot hand in I/O at­tracts a $93M trans-Pa­cif­ic ven­ture round

7 years ago
Financing

Mer­ck, Am­gen back a $30M play for Ri­bometrix — one of the up­starts mak­ing its mark in drug­ging RNA

7 years ago
Financing

Con­cert’s ini­tial alope­cia da­ta fall short against Pfiz­er, prompt­ing in­vestor blow back

7 years ago
R&D

Nestlé ups its bet on Aim­mune’s peanut al­ler­gy drug to $276M as NDA fil­ing looms, ri­val­ry in­ten­si­fies

7 years ago
Pharma
First page Previous page 981982983984985986987 Next page Last page
A service from the Financial Times